Articles related to Radiology

Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.

US News & World Report recently published its state healthcare rankings, based on three measures: access to healthcare, quality of care, and overall health of the population, measuring rates of obesity, smoking, suicide, mental health, and mortality for adults and infants. At the top, Hawaii was the clear winner. At the bottom, Mississippi. Where does your state measure up in the rankings?

The IRS was kind enough to move the traditional tax deadline from April 15 to Monday, May 17, granting a bit of a reprieve for getting your financial affairs in order. Many physicians choose to handle their taxes themselves despite a good CPA paying for him/herself in the deductions and tax-savings strategies that they find for you. If you decide to go this route, here are some things you should be asking.

In this podcast/article from KevinMD, the story of Dr. Hasan Gokal is examined, a Houston physician who was fired from his public health job and was subsequently faced with criminal charges for stealing a vial of the vaccine. His case was also brought to the Texas Medical Board. In a sea of regulations and protocols, were his actions well-intentioned and in the best interest of patient care and safety?

The approval of the drug (Fotivda, Aveo Pharmaceuticals) was based on the results of the open-label, multi-center TIVO-3 trial, which looked at progression-free survival (PFS) as the main efficacy endpoint, assessed by a blinded independent radiology review committee. Secondary end points included overall survival (OS) and objective response rate (ORR).

This article from Radiopaedia discusses inclusions, usage, assessment of treatment response, caveats, history, and etymology of the internationally recognized Deauville five-point scale (Deauville 5PS), which was proposed in an international workshop attended by hematologists and nuclear medicine specialists in Deauville, France in 2009.